The chronic sialorrhea market was valued at USD 798.53 Million in 2025. It is expected to grow at a CAGR of 4.91% during the forecast period of 2026-2035 and attain a market value of USD 1289.62 Million by 2035. The market growth is propelled by the increasing adoption of botulinum toxin therapies and advancements in pharmacological treatments such as anticholinergics for symptom control. Growing awareness of neurological disorders associated with sialorrhea and the introduction of minimally invasive procedures are projected to enhance market growth during the forecast period.
Base Year
Historical Period
Forecast Period
The market growth can be attributed to the growing geriatric population and rising incidence of neurological disorders.
The increasing research and development activities to bring novel therapeutics and treat the condition efficiently are poised to drive market growth in the forecast period.
Drug approvals by regulatory authorities are playing a significant role in market expansion, bolstering growth.
Compound Annual Growth Rate
4.91%
Value in USD Million
2026-2035
*this image is indicative*
Sialorrhea is a saliva-related medical condition that is also known as hypersalivation or excessive drooling. It is commonly of two types, namely, anterior sialorrhea and posterior sialorrhea. In anterior sialorrhea, excessive salivation is experienced by the patient running down from his/her mouth, leading to difficulty with cleanliness, skincare, and socialization. On the contrary, when patients are suffering from posterior sialorrhea, they experience excessive posterior spillage of saliva from their mouths down their airways (tracheas). This usually leads to chronic lung irritation.
The market for chronic sialorrhea is impacted by the rising incidence of neurological conditions that stimulate this condition. Moreover, a surge in research and development initiatives to offer improved and efficient treatment to patients is one of the significant market trends. The key players in the market are involved in continuous mergers and collaborations to develop novel treatment alternatives that cater to a wide range of affected individuals.
Regulatory Approvals Supporting Market Expansion
The market is experiencing an increased awareness about the serious repercussions of sialorrhea contributing to increased therapeutics developments, propelling market growth. The rising number of regulatory approvals by the authorities for drugs indicated for the treatment of chronic sialorrhea in children and adults is bolstering market growth. For instance, in November 2023, the Therapeutic Goods Administration (TGA) in Australia approved the use of XEOMIN by Merz Therapeutics for the treatment of children and adults suffering from chronic sialorrhea. This approval marked a significant milestone in the market as the XEOMIN is the first ever neurotoxin that has been approved by the regulatory authorities to treat the condition in Australia.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Prevalence of Neurological Disorders | The rising prevalence of chronic neurological disorders such as Parkinson’s disease, cerebral palsy, and ALS are closely related to sialorrhea making it a critical medical condition. |
| Advancements in Treatments | The key players are highly involved in bringing advanced treatments to the market including pharmacological and non-pharmacological treatments. Growing preference for surgical treatments and oral devices in the production of excessive saliva management is influencing the market. |
| Focus on Quality Lifestyle | Due to the psychological impact of this condition, the patient is required to maintain a positive lifestyle. The patients suffering from the condition usually face embarrassment, especially the ones dependent on others. Therefore, proper management and supervision of such patients are necessary for a better lifestyle. |
| Development of Novel Therapies | The market is witnessing substantial involvement of key players in introducing novel treatment therapies for chronic sialorrhea. The market players have a strong pipeline of upcoming new therapeutics, leading to market expansion. |
“Chronic Sialorrhea Market Report and Forecast 2026-2035” offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Treatment
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Segmentation Based on Treatment Leads the Market Share
The market segmentation based on treatment is bifurcated into pharmacological treatments and invasive treatments. Pharmacological treatments are further bifurcated into anticholinergics and botulinum toxin including glycopyrrolate, scopolamine, and tropicamide, among others, and IncobotulinumtoxinA (Xeomin), and RimabotulinumtoxinB (Myobloc) respectively. The market share is expected to be led by pharmacological treatments due to their effectiveness and non-invasive experience. However, the treatment depends on the severity of the condition along with the patient profile. Therefore, invasive treatments which include surgery and radiotherapy are also expected to hold a notable market share in the forecast period, based on the symptoms of the patient.
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States holds a significant share of the market majorly due to the growing geriatric population and rising prevalence of neurological conditions in the region. Neurological conditions such as Parkinson’s disease, and ALS, among others, are major conditions contributing to the occurrence of chronic sialorrhea in the region. The presence of robust healthcare infrastructure is also bolstering market growth as advanced technologies and medical facilities are highly reliable in the region.
EU-4 which includes countries Germany, France, Italy, and Spain along with the United Kingdom are likely to witness significant market growth in the forecast period. The market growth can be attributed to the presence of key academic institutions which are engaged in advanced research to develop high-efficacy treatments for the condition.
The key features of the market report comprise patent analysis, clinical trial analysis, grants analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Based in Louisville, Kentucky, it is an American speciality pharmaceutical company. The company specializes in developing licenses for unique healthcare products to support better patient outcomes and bridge the gap of unmet needs in the market. The company portfolio primarily focuses on neurology, oncology, and critical care.
Headquartered in Frankfurt, Germany, the company is a parent pharmaceutical company of independent businesses in several domains including aesthetic medicine, therapeutic medicine (neurological movement disorders included), and wellness and beauty products.
Headquartered in New York City, USA, the company is a multinational pharmaceutical and biotechnology corporation. The company specialises in developing and manufacturing medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.
Based in Paris, France, it is a French biopharmaceutical company with a primary focus on drug development and commercialisation in oncology, rare disease, and neuroscience domains.
Based in Tel Aviv, Israel, the multinational pharmaceutical company focuses primarily on developing generic drugs. Additionally, the company is the largest manufacturer of generic drugs in the world.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Boehringer Ingelheim International GmbH, GSK Plc, Bayer AG, McKesson Medical-Surgical Inc., Aurobindo Pharma Ltd., and Hikma Pharmaceuticals PLC.
Upto 15% Off
USD
$5499 $4949
$3299 $2969
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share